{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:41Z","timestamp":1791650561004,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Real-world evidence regarding enfortumab vedotin for unresectable or metastatic urothelial carcinoma is scarce, particularly in Japan. We investigated real-world data focusing on patient background, previous treatments, response, survival and adverse events in patients receiving enfortumab vedotin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A multicentre database was used to register 556 patients diagnosed with metastatic urothelial carcinoma from 2008 to 2023; 34 patients (6.1%) treated with enfortumab vedotin were included. Best radiographic objective responses were evaluated using the Response Evaluation Criteria in Solid Tumors (v1.1) during treatments. Overall survival and progression-free survival were estimated (Kaplan\u2013Meier method). Toxicities were reported according to the Common Terminology Criteria for Adverse Events, version 5.0. The relative dose intensity, which could impact oncological outcomes, was calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The median number of enfortumab vedotin therapy cycles was 5. The best objective response to enfortumab vedotin was partial response, stable disease and progressive disease in 19 (56%), 5 (15%) and 10 (29%) patients, respectively. The median overall survival and progression-free survival after the first enfortumab vedotin dose were 16 and 9\u00a0months, respectively. No significant relationship was observed between survival outcomes after enfortumab vedotin initiation and the enfortumab vedotin relative dose intensity. The median overall survival from first-line platinum-based chemotherapy initiation was 42\u00a0months. Twenty-six (76%) patients experienced any grade of enfortumab vedotin-related toxicities; eight (24%) experienced Grades 3\u20134 toxicities, the most common being skin toxicity (any grade, 47%; Grades 3\u20134, 12%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Here, we report real-world evidence for enfortumab vedotin therapy in Japan. Tumour responses and safety profiles were comparable with those of clinical trials on this novel treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyad170","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T04:44:12Z","timestamp":1702010652000},"page":"329-338","source":"Crossref","is-referenced-by-count":37,"title":["Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"first","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"},{"name":"Department of Urology, Hirao Hospital , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oda","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Takai Hospital , Tenri, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Ohmori","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Prefecture General Medical Center , Nara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimi","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Department of Urology, Yamatotakada Municipal Hospital , Yamatotakada, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Itami","sequence":"additional","affiliation":[{"name":"Department of Urology, Tane General Hospital , Osaka, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Urology, Hoshigaoka Medical Center , Hirakata, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Hoshigaoka Medical Center , Hirakata, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kiba","sequence":"additional","affiliation":[{"name":"Department of Urology, Kindai University Nara Hospital , Ikoma, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Tomioka","sequence":"additional","affiliation":[{"name":"Department of Urology, Saiseikai Chuwa Hospital , Sakurai, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Minami Nara Medical Center , Yoshino, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eijiro","family":"Okajima","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara City Hospital , Nara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuwata","family":"Masaomi","sequence":"additional","affiliation":[{"name":"Department of Urology, Matsusaka Chuo General Hospital , Matsusaka, Mie , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keichi","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Osaka Kaisei Hospital , Osaka, Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Tomizawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Morizawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Torimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"},{"name":"Department of Prostate Brachytherapy, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University , Kashihara, Nara , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Nara Urological Research and Treatment Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2024031106210973800_ref1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2024031106210973800_ref2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/jjco\/hyx017","article-title":"Incidence rate for bladder cancer in Japanese in Japan and in the United States from the cancer incidence in five continents","volume":"47","author":"Matsuda","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210973800_ref3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2147\/CEOR.S264942","article-title":"Treatment sequencing patterns in patients with metastatic urothelial cancer treated in the community practice setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)","volume":"12","author":"Doshi","year":"2020","journal-title":"Clinicoecon Outcomes Res"},{"key":"2024031106210973800_ref4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2147\/CMAR.S348899","article-title":"Significant improvement of prognosis after the advent of immune checkpoint inhibitors in patients with advanced, unresectable, or metastatic urothelial carcinoma: a propensity score matching and inverse probability of treatment weighting analysis on real-world data","volume":"14","author":"Miyake","year":"2022","journal-title":"Cancer Manag Res"},{"key":"2024031106210973800_ref5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/iju.14601","article-title":"Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: a multicenter retrospective study","volume":"28","author":"Narita","year":"2021","journal-title":"Int J Urol"},{"key":"2024031106210973800_ref6","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1111\/iju.15014","article-title":"Improved survival in real-world patients with advanced urothelial carcinoma: a multicenter propensity score-matched cohort study comparing a period before the introduction of pembrolizumab (2003-2011) and a more recent period (2016-2020)","volume":"29","author":"Taguchi","year":"2022","journal-title":"Int J Urol"},{"key":"2024031106210973800_ref7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1093\/jjco\/hyac186","article-title":"Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study","volume":"53","author":"Miyake","year":"2023","journal-title":"Jpn J Clin Oncol"},{"key":"2024031106210973800_ref8","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"2024031106210973800_ref9","doi-asserted-by":"crossref","first-page":"196.e1","DOI":"10.1016\/j.clgc.2021.11.006","article-title":"Response to Pembrolizumab after dose-reduced cisplatin plus gemcitabine chemotherapy is inferior to that after carboplatin plus gemcitabine chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma","volume":"20","author":"Miyake","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"2024031106210973800_ref10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"2024031106210973800_ref11","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","article-title":"Interpretation and impact of real-world clinical data for the practicing clinician","volume":"35","author":"Blonde","year":"2018","journal-title":"Adv Ther"},{"key":"2024031106210973800_ref12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.euros.2023.04.018","article-title":"Enfortumab vedotin in metastatic urothelial carcinoma: survival and safety in a European multicenter real-world patient cohort","volume":"53","author":"Zsch\u00e4bitz","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2024031106210973800_ref13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2288-11-40","article-title":"Opt-out as an acceptable method of obtaining consent in medical research: a short report","volume":"11","author":"Vellinga","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"2024031106210973800_ref14","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2024031106210973800_ref15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2024031106210973800_ref16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/iju.14281","article-title":"Clinical practice guidelines for bladder cancer 2019 update by the Japanese Urological Association: summary of the revision","volume":"27","author":"Matsumoto","year":"2020","journal-title":"Int J Urol"},{"key":"2024031106210973800_ref17","volume-title":"Eur Urol"},{"key":"2024031106210973800_ref18","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2024031106210973800_ref19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/cncr.34057","article-title":"Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study","volume":"128","author":"Koshkin","year":"2022","journal-title":"Cancer"},{"key":"2024031106210973800_ref20","doi-asserted-by":"crossref","DOI":"10.1111\/iju.15300","article-title":"Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: a multicenter propensity score-matched study","author":"Taguchi","year":"2023","journal-title":"Int J Urol"},{"key":"2024031106210973800_ref21","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.3390\/cancers15174227","article-title":"Administration of enfortumab vedotin after immune-checkpoint inhibitor and the prognosis in Japanese metastatic urothelial carcinoma: a large database study on enfortumab vedotin in metastatic urothelial carcinoma","volume":"15","author":"Kawahara","year":"2023","journal-title":"Cancers"},{"key":"2024031106210973800_ref22","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"key":"2024031106210973800_ref23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2022.12.009","article-title":"In patients with advanced urothelial carcinoma, immune checkpoint inhibition prior to enfortumab vedotin is associated with high-grade skin toxicity","volume":"83","author":"Molina","year":"2023","journal-title":"Eur Urol"},{"key":"2024031106210973800_ref24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.euros.2023.01.002","article-title":"Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: a single-center experience and review of the literature","volume":"49","author":"Vlachou","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"2024031106210973800_ref25","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1007\/s10637-019-00844-x","article-title":"A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Takahashi","year":"2020","journal-title":"Invest New Drugs"},{"key":"2024031106210973800_ref26","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1200\/JCO.2023.41.6_suppl.508","article-title":"Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): long-term follow-up from the JAVELIN bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy","volume":"41","author":"Sridhar","year":"2023","journal-title":"J Clin Oncol"},{"key":"2024031106210973800_ref27","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cam4.5165","article-title":"Japanese subgroup analysis of EV-301: an open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma","volume":"12","author":"Matsubara","year":"2023","journal-title":"Cancer Med"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/329\/56912483\/hyad170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/54\/3\/329\/56912483\/hyad170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:26:10Z","timestamp":1710138370000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/54\/3\/329\/7462058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,12,7]]},"published-print":{"date-parts":[[2024,3,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyad170","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,12,7]]}}}